These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 6384253)

  • 1. Pharmacokinetics of gonadotropin-releasing hormone: comparison of subcutaneous and intravenous routes.
    Handelsman DJ; Jansen RP; Boylan LM; Spaliviero JA; Turtle JR
    J Clin Endocrinol Metab; 1984 Oct; 59(4):739-46. PubMed ID: 6384253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous administration of gonadotropin-releasing hormone: absorption kinetics and gonadotropin responses.
    Hurley DM; Clarke IJ; Shelton R; Burger HG
    J Clin Endocrinol Metab; 1987 Jul; 65(1):46-52. PubMed ID: 3108305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulsatile luteinizing hormone releasing hormone treatment for induction of ovulation. Radioimmunoassay of plasma LHRH and comparative study of subcutaneous versus intravenous routes of administration.
    Couzinet B; Lahlou N; Lestrat N; Bouchard P; Roger M; Schaison G
    J Endocrinol Invest; 1986 Apr; 9(2):103-8. PubMed ID: 3519743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics of gonadotropin-releasing hormone (GnRH). II. Pattern of GnRH delivery alters pituitary luteinizing hormone secretion in women.
    Handelsman DJ; Boylan LM
    J Clin Endocrinol Metab; 1988 Jul; 67(1):175-9. PubMed ID: 3132482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of subcutaneous and intranasal administration of ovine corticotropin-releasing hormone in man: comparison with intravenous administration.
    DeBold CR; Sheldon WR; DeCherney GS; Jackson RV; Nicholson WE; Island DP; Orth DN
    J Clin Endocrinol Metab; 1985 May; 60(5):836-40. PubMed ID: 2984233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma gonadotropin-releasing hormone profiles after intravenous and subcutaneous bolus injection in thin and obese women.
    Lyles R; Elkind-Hirsch K; Goldzieher JW; Besch PK
    Obstet Gynecol; 1988 Jan; 71(1):44-8. PubMed ID: 3122139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypogonadotropic hypogonadism: hormonal responses to low dose pulsatile administration of gonadotropin-releasing hormone.
    Valk TW; Corley KP; Kelch RP; Marshall JC
    J Clin Endocrinol Metab; 1980 Oct; 51(4):730-8. PubMed ID: 6774991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Derangement of pituitary gonadotropin release with different GnRH pulsatile patterns in chronic intravenous or subcutaneous delivery.
    Souvatzoglou A; Voulgaris Z; Charitopoulou R; Rapti E
    J Endocrinol Invest; 1986 Aug; 9(4):325-30. PubMed ID: 3097115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin pharmacokinetics following continuous infusion and bolus injection of regular porcine and human insulin in healthy man.
    Waldhäusl WK; Bratusch-Marrain PR; Vierhapper H; Nowotny P
    Metabolism; 1983 May; 32(5):478-86. PubMed ID: 6341763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Model of the distribution and metabolism of the gonadotropin-releasing hormone (GnRH) agonist [D-Trp6,Des-Gly-NH2(10)]GnRH ethylamide in man.
    Candas B; Lacoste D; Normand M; Labrie F
    J Clin Endocrinol Metab; 1990 Apr; 70(4):1046-54. PubMed ID: 2180974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiation of male hypogonadotropic hypogonadism and constitutional delay of puberty by pulsatile administration of gonadotropin-releasing hormone.
    Partsch CJ; Hermanussen M; Sippell WG
    J Clin Endocrinol Metab; 1985 Jun; 60(6):1196-203. PubMed ID: 3923024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
    Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
    J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of ovulation with pulsatile GnRH: comparison between subcutaneous and intravenous administration in the same patients.
    Riolo A; Carioni E; Lerro S; Albano M; Crippa A; Gelli D; Bini M; Pisoni P
    Acta Eur Fertil; 1987; 18(4):271-5. PubMed ID: 3134780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of administration of a gonadotropin-releasing hormone (GnRH) antagonist (Nal-Glu) during the periovulatory period: the luteinizing hormone surge requires secretion of GnRH.
    Dubourdieu S; Charbonnel B; D'Acremont MF; Carreau S; Spitz IM; Bouchard P
    J Clin Endocrinol Metab; 1994 Feb; 78(2):343-7. PubMed ID: 8106622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of human follicle-stimulating hormone in gonadotropin-deficient men.
    Handelsman DJ; Turner L; Boylan LM; Conway AJ
    J Clin Endocrinol Metab; 1995 May; 80(5):1657-63. PubMed ID: 7745014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dynamics of gonadotropin inhibition in women induced by an antagonistic analog of gonadotropin-releasing hormone.
    Cetel NS; Rivier J; Vale W; Yen SS
    J Clin Endocrinol Metab; 1983 Jul; 57(1):62-5. PubMed ID: 6406535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The nature of the gonadotropin-releasing hormone stimulus-luteinizing hormone secretory response of human gonadotrophs in vivo.
    Veldhuis JD; O'Dea LS; Johnson ML
    J Clin Endocrinol Metab; 1989 Mar; 68(3):661-70. PubMed ID: 2645313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous infusion versus daily injections of growth hormone (GH) for 4 weeks in GH-deficient patients.
    Laursen T; Jørgensen JO; Jakobsen G; Hansen BL; Christiansen JS
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2410-8. PubMed ID: 7543114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-day pulsatile gonadotropin-releasing hormone administration unveils combined hypothalamic-pituitary-gonadal defects underlying profound hypoandrogenism in men with prolonged critical illness.
    van den Berghe G; Weekers F; Baxter RC; Wouters P; Iranmanesh A; Bouillon R; Veldhuis JD
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3217-26. PubMed ID: 11443192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of intravenous, subcutaneous, and intranasal administration of growth hormone (GH)-releasing hormone-40 on serum GH concentrations in normal men.
    Evans WS; Vance ML; Kaiser DL; Sellers RP; Borges JL; Downs TR; Frohman LA; Rivier J; Vale W; Thorner MO
    J Clin Endocrinol Metab; 1985 Nov; 61(5):846-50. PubMed ID: 3930551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.